null Stéphane Laporte, PhD

Senior Scientist, RI-MUHC, Glen site

Metabolic Disorders and Complications Program

Centre for Translational Biology

Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Endocrinology, MUHC



G protein-coupled receptor • molecular pharmacology • cell imaging • cardiovascular diseases • pre-term birth.

Research Focus

My research focuses on understanding the molecular and cellular mechanisms regulating G protein-coupled receptors (GPCRs), a class of membrane receptor that is involved in many physiological responses, and is the target of more than 30% of marked drugs. We are interested in the development of novel molecules with allosteric, biased signaling modes of action, in particular for the prostanglandin PG2α (FP) receptor, which will redirect signaling responses in cells. Using innovative imaging and biophysical approaches, we also study the dynamics of protein complexes involved in receptor trafficking and signaling for different GPCRs, in particular for the angiotensin II type 1. My laboratory is involved in developing novel fluorescently tagged biosensors for studying GPCR signaling and trafficking in live cells, with the goal of identifying small molecules that regulate these processes. Our research program aims to provide new insights into the molecular details of GPCR signaling and trafficking, with the goal of identifying new means to improve hormone and drug efficacy, especially in cardiovascular diseases, inflammation, pre-term birth and cancer.

Selected Publications

Click on Pubmed to see my current publications list

  • Unraveling allostery within the angiotensin II type 1 receptor for Gαq and β-arrestin coupling. Cao Y, van der Velden WJC, Namkung Y, Nivedha AK, Cho A, Sedki D, Holleran B, Lee N, Leduc R, Muk S, Le K, Bhattacharya S, Vaidehi N, Laporte SA. Sci Signal. 2023 Aug 8;16(797):eadf2173. doi: 10.1126/scisignal.adf2173. Epub 2023 Aug 8. PMID: 37552769.

  • Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen. Giubilaro J, Schuetz DA, Stepniewski TM, Namkung Y, Khoury E, Lara-Márquez M, Campbell S, Beautrait A, Armando S, Radresa O, Duchaine J, Lamarche-Vane N, Claing A, Selent J, Bouvier M, Marinier A, Laporte SA. Nat Commun. 2021 Aug 3;12(1):4688. doi: 10.1038/s41467-021-24968-y. PMID: 34344896.

  • Signal profiling of the β1AR reveals coupling to novel signalling pathways and distinct phenotypic responses mediated by β1AR and β2AR.Lukasheva V, Devost D, Le Gouill C, Namkung Y, Martin RD, Longpré JM, Amraei M, Shinjo Y, Hogue M, Lagacé M, Breton B, Aoki J, Tanny JC, Laporte SA, Pineyro G, Inoue A, Bouvier M, Hébert TE. Sci Rep. 2020 May 29;10(1):8779. doi: 10.1038/s41598-020-65636-3. PMID: 32471984.

  • Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors.Namkung Y, LeGouill C, Kumar S, Cao Y, Teixeira LB, Lukasheva V, Giubilaro J, Simões SC, Longpré JM, Devost D, Hébert TE, Piñeyro G, Leduc R, Costa-Neto CM, Bouvier M, Laporte SA. Sci Signal. 2018 Dec 4;11(559):eaat1631. doi: 10.1126/scisignal.aat1631. PMID: 30514808.

  • Manifold roles of β-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9 .Luttrell LM, Wang J, Plouffe B, Smith JS, Yamani L, Kaur S, Jean-Charles PY, Gauthier C, Lee MH, Pani B, Kim J, Ahn S, Rajagopal S, Reiter E, Bouvier M, Shenoy SK, Laporte SA, Rockman HA, Lefkowitz RJ. Sci Signal. 2018 Sep 25;11(549):eaat7650. doi: 10.1126/scisignal.aat7650. PMID: 30254056.